Liposomal Bupivacaine Cuts Movement Pain After CRS + HIPEC
This placebo-controlled trial shows incisional liposomal bupivacaine added to opioid PCIA markedly reduces early movement-evoked pain after cytoreductive surgery, but only modestly reduces opioid use and does not improve recovery quality.
📅 Journal publication: Oct 2026(online Aug 2, 2026)·Last updated: Oct 6, 2026
Can liposomal bupivacaine revolutionize post-surgical pain management in CRS + HIPEC?
Managing postoperative pain after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is challenging, and new solutions like liposomal bupivacaine could enhance recovery. Liposomal bupivacaine reduced movement-evoked pain from 70.8% to 19.6% within 72 hours compared to saline and decreased opioid use with no significant difference in quality of recovery. This study suggests potential benefits of liposomal bupivacaine over saline in managing incisional pain post-CRS + HIPEC, though not more effective than other existing analgesic methods. Liposomal bupivacaine offers effective pain reduction after CRS + HIPEC but is not superior to all standard techniques.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Zhang H, Gong Z, Li Y, Li B, Yu Y, Liu G, Ji Z, Zhang H, Yan S
Citation:Zhang H, Gong Z, Li Y, et al. Liposomal Bupivacaine Incisional Infiltration for Postoperative Analgesia After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: A Randomized Placebo-Controlled Trial. Pain and therapy. 2026;15(5):1569-1590. doi:10.1007/s40122-026-00876-1